Abstract:Liver fibrosis is a key process in the progression of chronic liver disease to cirrhosis. Currently, early diagnosis and precise staging of liver fibrosis remain great challenges. Extracellular matrix (ECM) molecules expressed specifically during liver fibrosis are ideal targets for bioimaging and detection of liver fibrosis. Here, we report that fluorescent probes based on a nucleic acid aptamer (ZY-1) targeting cellular fibronectin (cFN), a critical ECM molecule significantly accumulating during liver fibrosis, are promising bioimaging agents for the staging of liver fibrosis. In the work, the outstanding binding affinity of ZY-1 to cFN was validated through an in vitro model of human-derived hepatic stellate cells (HSCs). Subsequently, we constructed different ZY-1-based fluorescent probes and explored the real-time imaging performance of these fluorescent probes in CCl 4 -induced mouse models of different liver fibrosis stages. The ZY-1-based fluorescent probes, for the first time, effectively identified and distinguished early-stage liver fibrosis (stage 3 of Ishak 6) from advanced liver fibrosis (stage 5 of Ishak 6). The proof-of-concept study provides compelling evidences that ZY-1-based probes are a promising tool for the early diagnosis and staging of liver fibrosis and paves the way for further development of clinical-related diagnosis strategies for fibrotic diseases of the liver and other organs. Statement of significance Currently, early diagnosis and accurate staging of liver fibrosis continue to present significant challenges. This study demonstrates that fluorescent probes based on the nucleic acid aptamer ZY-1, which targets cellular fibronectin (cFN)—a crucial extracellular matrix (ECM) molecule that significantly accumulates during liver fibrosis—are promising bioimaging agents for staging liver fibrosis. The ZY-1-based fluorescent probes effectively identified and differentiated early-stage liver fibrosis from advanced liver fibrosis. This proof-of-concept study not only provides compelling evidence that ZY-1-based probes show promise for the early diagnosis and staging of liver fibrosis but also paves the way for further investigations into the use of ZY-1 in detecting other diseases associated with cFN.

In vitro and in vivo activation of mouse liver astral cell by confocal raman microspectroscopy

Study On The In Vitro And In Vivo Activation Of Rat Hepatic Stellate Cells By Raman Spectroscopy (Vol 12, Art No 034003, 2007)

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Dynamic Changes of Key Metabolites During Liver Fibrosis in Rats.

Molecular magnetic resonance imaging of activated hepatic stellate cells with ultrasmall superparamagnetic iron oxide targeting integrin αvβ3 for staging liver fibrosis in rat model

Molecular Magnetic Resonance Imaging of Activated Hepatic Stellate Cells with Ultrasmall Superparamagnetic Iron Oxide Targeting Integrin αvβ3 for Staging Liver Fibrosis in Rat Model

Recent advances in molecular magnetic resonance imaging of liver fibrosis.

Discrimination of lipid composition and cellular localization in human liver tissues by stimulated Raman scattering microscopy

Molecular Imaging of Hepatic Stellate Cell Activity by Visualization of Hepatic Integrin Αvβ3 Expression with SPECT in Rat

Targeting Activated Hepatic Stellate Cells (ahscs) for Liver Fibrosis Imaging

Novel Strategy for Validating the Existence and Mechanism of the "gut-liver axis" in Vivo by a Hypoxia-Sensitive NIR Fluorescent Probe.

In Vivo Study on the Protection of Indole‐3‐carbinol (I3C) Against the Mouse Acute Alcoholic Liver Injury by Micro‐raman Spectroscopy

Serological Diagnosis Of Liver Fibrosis By Quantitative Estimation Of Serum Biomarkers Using Luminex Xmap Assay

MR Imaging of Activated Hepatic Stellate Cells in Liver Injured by CCl 4 of Rats with Integrin-Targeted Ultrasmall Superparamagnetic Iron Oxide

Enhanced US/CT/MR imaging of integrin αvβ3 for liver fibrosis staging in rat

Hepatic Stellate Cell-Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis

In Vivo Lipid Profiling Using Proton Magnetic Resonance Spectroscopy in an Experimental Liver Fibrosis Model.

[18F]AlF-ND-bisFAPI PET imaging of fibroblast activation protein as a biomarker to monitor the progression of liver fibrosis

Cellular fibronectin-targeted fluorescent aptamer probes for early detection and staging of liver fibrosis

A novel alternative strategy for monitoring and insight into liver fibrosis progression: The combination of surface-enhanced Raman spectroscopy (SERS) and gut microbiota

Classification and prediction of HCC tissues by Raman imaging with identification of fatty acids as potential lipid biomarkers